Krystal Biotech Announces $400 Million Share Repurchase Program and Revises 2026 Operating Expense Guidance
Krystal Biotech (KRYS) reported strong third-quarter results, driven by $127.3 million in revenue from its product VYJUVEK. The company maintains a robust liquidity position, ending September with $1.2 billion in cash and investments. CEO Krish Krishnan characterized the quarter as another period of significant strength for the organization. Looking ahead, Krystal Biotech has outlined a strategic capital allocation plan involving a $400 million share repurchase program to be executed over the next two years. Additionally, the company provided updated financial guidance, revising its 2026 non-GAAP operating expenses to a range of $155 million to $165 million.
Tickers: $KRYS
Topics: cash position earnings report revenue growth VYJUVEK revenue
Read the full article at Seeking Alpha
Part of the story Dominari Holdings Executes $3.4 Million of $5 Million Share Repurchase Program (11 articles)